New York, NY (PRWEB) May 15, 2013
Pradaxa lawsuit filings continue to mount in the federal multidistrict litigation now underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to the Court’s website, 705 claims have been filed in the litigation on behalf of individuals who allegedly suffered life-threatening internal bleeding while using Pradaxa.( In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
“We are not at all surprised that the filings in this litigation are increasing at such a rapid pace. Our Firm continues to hear from alleged victims of Pradaxa side effects on a regular basis,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Pradaxa bleeding.
Pradaxa Side Effects
Pradaxa was approved for sale by the U.S. Food & Drug Administration (FDA) in October 2010 to prevent strokes in people with atrial fibrillation. The drug was touted as an improvement over decades-old warfarin, but Bloomberg.com reported in December that regulators in several countries have issued alerts regarding the drug’s potential to cause dangerous internal bleeding in some patients. Most problematic is the fact that there exists no readily-available antidote for internal bleeding, a potentially life-threatening Pradaxa side effect. *
In January, an analysis of FDA hemorrhage cases published in the Institute for Safe Medication Practice’s QuarterWatch report revealed Pradaxa bleeding to be 5 times more likely to result in death compared to warfarin bleeding.** Most recently, a study published May 1st in the Journal of Neurosurgery found that head trauma victims were more likely to die from brain bleeding if they had been using Pradaxa compared to those taking warfarin. The study authors surmised that the lack of an effective reversal agent could account for the higher death rate among Pradaxa patients.***
Court documents indicate that the first trial in the federal Pradaxa litigation is scheduled to begin in September 2014. Plaintiffs with claims pending in the litigation allege that Boehringer Ingelheim failed to adequately warn that there is no readily-available antidote for Pradaxa bleeding.
Victims of serious Pradaxa side effects may be eligible to collect compensation for their medical bills, lost wages, pain and suffering and more. Additional information regarding Pradaxa lawsuits is available at Bernstein Liebhard LLP’s website. To arrange for a free legal consultation, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com